These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 14616974)

  • 1. Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model.
    Schatz S; Turecek PL; Fiedler C; Zimmermann K; Gritsch H; Voorberg J; Schwarz HP; Dorner F; Scheiflinger F
    Br J Haematol; 2003 Nov; 123(4):692-5. PubMed ID: 14616974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced thrombin sensitivity of a factor VIII-heparin cofactor II hybrid.
    Voorberg J; van Stempvoort G; Bos JM; Mertens K; van Mourik JA; Donath MJ
    J Biol Chem; 1996 Aug; 271(35):20985-8. PubMed ID: 8702860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).
    Pastoft AE; Lykkesfeldt J; Ezban M; Tranholm M; Whinna HC; Lauritzen B
    Haemophilia; 2012 Sep; 18(5):782-8. PubMed ID: 22500820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
    Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
    Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
    Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
    Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative and humane tail bleeding assay for efficacy evaluation of antihaemophilic factors in haemophilia A mice.
    Molina ES; Fujita A; Sogayar MC; Demasi MA
    Haemophilia; 2014 Nov; 20(6):e392-8. PubMed ID: 24975823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
    Fernández-Bello I; Rode F; Álvarez-Román MT; Butta NV; Rivas-Muñoz S; Hernández-Moreno AL; de la Corte-Rodríguez H; Martín-Salces M; Larsen LF; Jiménez-Yuste V
    Eur J Pharm Sci; 2019 Feb; 128():215-221. PubMed ID: 30529268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.
    Johansen PB; Tranholm M; Haaning J; Knudsen T
    Haemophilia; 2016 Jul; 22(4):625-31. PubMed ID: 26936336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
    Hansson KM; Lindblom A; Elg M; Lövgren A
    Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of glycosaminoglycans with heparin cofactor II.
    Tollefsen DM
    Ann N Y Acad Sci; 1994 Apr; 714():21-31. PubMed ID: 8017769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose of human plasma-derived FVIII-VWF as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review.
    Zanon E; Milan M; Brandolin B; Barbar S; Spiezia L; Saggiorato G; Simioni P; Baudo F
    Haemophilia; 2013 Jan; 19(1):e50-3. PubMed ID: 23051581
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.
    Gale AJ; Bhat V; Pellequer JL; Griffin JH; Mosnier LO; Von Drygalski A
    Pharm Res; 2016 Jun; 33(6):1517-26. PubMed ID: 26960296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin cofactor II as a novel vascular protective factor against atherosclerosis.
    Aihara K; Azuma H; Akaike M; Sata M; Matsumoto T
    J Atheroscler Thromb; 2009 Oct; 16(5):523-31. PubMed ID: 19729870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin cofactor II modulates the response to vascular injury.
    Tollefsen DM
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
    Samuelson Bannow B; Recht M; Négrier C; Hermans C; Berntorp E; Eichler H; Mancuso ME; Klamroth R; O'Hara J; Santagostino E; Matsushita T; Kessler C
    Blood Rev; 2019 May; 35():43-50. PubMed ID: 30922616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.
    Baumgartner CK; Zhang G; Kuether EL; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2015 Dec; 13(12):2210-9. PubMed ID: 26453193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.
    Mertens K; Donath MJ; van Leen RW; de Keyzer-Nellen MJ; Verbeet MP; Klaasse Bos JM; Leyte A; van Mourik JA
    Br J Haematol; 1993 Sep; 85(1):133-42. PubMed ID: 8251380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
    Klintman J; Astermark J; Berntorp E
    Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.
    De Cristofaro R; De Filippis V
    Biochem J; 2003 Jul; 373(Pt 2):593-601. PubMed ID: 12689334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.